Executive Outlook: Converting Innovative Science Into Predictable Returns

By Ben Comer, Chief Editor, Life Science Leader

It’s not all doom and gloom as 2023 comes to a close, although there is plenty of both to go around. Generalist investors haven’t found their way back to the sector, and a record number of biotechs declared bankruptcy this year. CMS selected the first round of drugs for price negotiation under the Inflation Reduction Act (IRA), and payer concerns about drug budgets in the context of innovative, late-stage therapies in industry pipelines are generating downward pricing pressure on multiple fronts, both private and public.